Status:
ACTIVE_NOT_RECRUITING
COVID-19 and Cancer Consortium Registry
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Conditions:
COVID-19
Invasive Malignancy (Any Type)
Eligibility:
All Genders
18+ years
Brief Summary
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized re...
Detailed Description
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate hypothesis-generat...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- • Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria:
- Suspected (presumptive positive based on clinical presentation) or lab-confirmed COVID-19.
- Current or past medical history of invasive malignancy (any type)
- Exclusion criteria:
- Participants at international sites not explicitly listed below
- Non-healthcare providers (or their proxies)
Exclusion
Key Trial Info
Start Date :
March 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2029
Estimated Enrollment :
19275 Patients enrolled
Trial Details
Trial ID
NCT04354701
Start Date
March 17 2020
End Date
December 1 2029
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232